Vensica Medical is developing a needle-free, painless procedure for the delivery of Botox® to treat overactive bladder.
The market seeks a safe, painless method to deliver Botox into the bladder wall.
Vensica is developing VensiCare, an ultrasound catheter used to deliver Botox into the bladder wall painlessly and without the use of needles. VensiCare leverages the known properties of ultrasound (opens pores in the tissue and “pushes” the drug through these pores). The procedure using the VensiCare system can be performed in the doctor’s office or clinic, without anesthesia. Read more about the idea behind Vensica’s VensiCare system.
Stage: Technology development
Founded: August 2014
Investor: The Trendlines Group
IP: Submitted one PCT application
Overactive bladder (OAB), characterized by the urgent need to urinate and involuntary loss of urine, has a negative impact on the quality of life. In 50% of the cases, medications are ineffective and often have significant side effects. In 2011, the FDA approved the use of Botox® to treat OAB. This procedure is performed using a cystoscope (to visualize the interior of the bladder) and a needle to inject the Botox. While Botox has demonstrated effectiveness in treating OAB, the procedure is expensive, painful (20-30 injection sites), risky (urinary tract infections), and in most cases performed under sedation.
OAB is the most common type of bladder disorder. There are 39 million people in the United States alone, and 4 million of them are unsatisfied with treatment.
Watch CEO Avner Geva's interview on Israel Daily TV.
See Avner Geva's presentation at Trendlines 6th Annual Company Showcase.
VensiCare is the needle-free, painless procedure to deliver Botox® to the bladder wall in the treatment of overactive bladder.
Portable, automatic system for peritoneal dialysis
Device for treating ischemic stroke
Anastomotic closure device for laparoscopic bowel resection
Miniature screwless spine fusion implant
Noninvasive monitoring for the diagnosis of heart failure